Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population
Shamira A Perera,1–3 Daniel SW Ting,1,2 Monisha E Nongpiur,1–3 Paul T Chew,3 Maria Cecilia D Aquino,3 Chelvin CA Sng,3 Sue-Wei Ho,1,2 Tin Aung1–3 1Singapore Eye Research Institute, Singapore; 2Singapore National Eye Centre, Singapore; 3Department of Ophthalmology, Yong...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-04-01
|
Series: | Clinical Ophthalmology |
Subjects: | |
Online Access: | https://www.dovepress.com/feasibility-study-of-sustained-release-travoprost-punctum-plug-for-int-peer-reviewed-article-OPTH |
id |
doaj-cf4746c7dc064d499a05bfedfcd92e62 |
---|---|
record_format |
Article |
spelling |
doaj-cf4746c7dc064d499a05bfedfcd92e622020-11-25T01:02:20ZengDove Medical PressClinical Ophthalmology1177-54832016-04-012016Issue 175776426635Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian populationPerera SATing DSWNongpiur MEChew PTAquino MCDSng CCAHo SWAung TShamira A Perera,1–3 Daniel SW Ting,1,2 Monisha E Nongpiur,1–3 Paul T Chew,3 Maria Cecilia D Aquino,3 Chelvin CA Sng,3 Sue-Wei Ho,1,2 Tin Aung1–3 1Singapore Eye Research Institute, Singapore; 2Singapore National Eye Centre, Singapore; 3Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore Purpose: To investigate the efficacy and safety of a punctum plug-based sustained drug release system for a prostaglandin analog, travoprost (OTX-TP), for intraocular pressure (IOP) ­reduction in an Asian population. Methods: This is an initial feasibility, prospective, single-arm study involving 26 eyes and a bioresorbable punctum plug containing OTX-TP. An OTX-TP was placed in the vertical portion of the superior or inferior canaliculus of patients with primary open-angle glaucoma or ocular hypertension. The main outcome measure was the IOP-lowering efficacy of OTX-TP at 3 (8 am) and 10, 20, and 30 days (8 am, 10 am, and 4 pm), compared to baseline. Results: A total of 26 OTX-TP were inserted for 17 subjects. The mean (standard deviation) age was 57.2 (13.8) years. At 10 days, all plugs were still present, and the IOP reduction from baseline was 6.2 (23%), 5.4 (21%), and 7.5 mmHg (28%) at 8 am, 10 am, and 4 pm, respectively. At 10 days, the mean IOP (standard error of mean) was 21.2 (1.2), 20.4 (0.8), and 19.7 (1.0) at 8 am, 10 am, and 4 pm, respectively, showing no discernible IOP trend during the course of the day. At 30 days, plug retention had declined to 42%, and the overall IOP reduction had decreased to 16%. Conclusion: The sustained-release OTX-TP is able to reduce IOP by 24% (day 10) and 15.6% (day 30), respectively. It is a potentially well-tolerable ocular hypotensive for glaucoma patients with a history of poor compliance. Keywords: ocular hypertension, travoprost, bioresorbable, punctum plug, glaucoma, Asianhttps://www.dovepress.com/feasibility-study-of-sustained-release-travoprost-punctum-plug-for-int-peer-reviewed-article-OPTHTravoprostPunctum Plug |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Perera SA Ting DSW Nongpiur ME Chew PT Aquino MCD Sng CCA Ho SW Aung T |
spellingShingle |
Perera SA Ting DSW Nongpiur ME Chew PT Aquino MCD Sng CCA Ho SW Aung T Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population Clinical Ophthalmology Travoprost Punctum Plug |
author_facet |
Perera SA Ting DSW Nongpiur ME Chew PT Aquino MCD Sng CCA Ho SW Aung T |
author_sort |
Perera SA |
title |
Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population |
title_short |
Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population |
title_full |
Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population |
title_fullStr |
Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population |
title_full_unstemmed |
Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population |
title_sort |
feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an asian population |
publisher |
Dove Medical Press |
series |
Clinical Ophthalmology |
issn |
1177-5483 |
publishDate |
2016-04-01 |
description |
Shamira A Perera,1–3 Daniel SW Ting,1,2 Monisha E Nongpiur,1–3 Paul T Chew,3 Maria Cecilia D Aquino,3 Chelvin CA Sng,3 Sue-Wei Ho,1,2 Tin Aung1–3 1Singapore Eye Research Institute, Singapore; 2Singapore National Eye Centre, Singapore; 3Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore Purpose: To investigate the efficacy and safety of a punctum plug-based sustained drug release system for a prostaglandin analog, travoprost (OTX-TP), for intraocular pressure (IOP) ­reduction in an Asian population. Methods: This is an initial feasibility, prospective, single-arm study involving 26 eyes and a bioresorbable punctum plug containing OTX-TP. An OTX-TP was placed in the vertical portion of the superior or inferior canaliculus of patients with primary open-angle glaucoma or ocular hypertension. The main outcome measure was the IOP-lowering efficacy of OTX-TP at 3 (8 am) and 10, 20, and 30 days (8 am, 10 am, and 4 pm), compared to baseline. Results: A total of 26 OTX-TP were inserted for 17 subjects. The mean (standard deviation) age was 57.2 (13.8) years. At 10 days, all plugs were still present, and the IOP reduction from baseline was 6.2 (23%), 5.4 (21%), and 7.5 mmHg (28%) at 8 am, 10 am, and 4 pm, respectively. At 10 days, the mean IOP (standard error of mean) was 21.2 (1.2), 20.4 (0.8), and 19.7 (1.0) at 8 am, 10 am, and 4 pm, respectively, showing no discernible IOP trend during the course of the day. At 30 days, plug retention had declined to 42%, and the overall IOP reduction had decreased to 16%. Conclusion: The sustained-release OTX-TP is able to reduce IOP by 24% (day 10) and 15.6% (day 30), respectively. It is a potentially well-tolerable ocular hypotensive for glaucoma patients with a history of poor compliance. Keywords: ocular hypertension, travoprost, bioresorbable, punctum plug, glaucoma, Asian |
topic |
Travoprost Punctum Plug |
url |
https://www.dovepress.com/feasibility-study-of-sustained-release-travoprost-punctum-plug-for-int-peer-reviewed-article-OPTH |
work_keys_str_mv |
AT pererasa feasibilitystudyofsustainedreleasetravoprostpunctumplugforintraocularpressurereductioninanasianpopulation AT tingdsw feasibilitystudyofsustainedreleasetravoprostpunctumplugforintraocularpressurereductioninanasianpopulation AT nongpiurme feasibilitystudyofsustainedreleasetravoprostpunctumplugforintraocularpressurereductioninanasianpopulation AT chewpt feasibilitystudyofsustainedreleasetravoprostpunctumplugforintraocularpressurereductioninanasianpopulation AT aquinomcd feasibilitystudyofsustainedreleasetravoprostpunctumplugforintraocularpressurereductioninanasianpopulation AT sngcca feasibilitystudyofsustainedreleasetravoprostpunctumplugforintraocularpressurereductioninanasianpopulation AT hosw feasibilitystudyofsustainedreleasetravoprostpunctumplugforintraocularpressurereductioninanasianpopulation AT aungt feasibilitystudyofsustainedreleasetravoprostpunctumplugforintraocularpressurereductioninanasianpopulation |
_version_ |
1725205510035079168 |